Immunic, Inc.
IMUX
$1.12
-$0.03-2.61%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.48% | 16.46% | 14.14% | 8.38% | 4.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.18% | -4.39% | -3.20% | 3.81% | 14.68% |
| Operating Income | 1.18% | 4.39% | 3.20% | -3.81% | -14.68% |
| Income Before Tax | -7.37% | 24.60% | 24.94% | 21.58% | 22.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.37% | 24.60% | 24.94% | 21.58% | 22.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.37% | 24.60% | 24.94% | 21.58% | 22.25% |
| EBIT | 1.18% | 4.39% | 3.20% | -3.81% | -14.68% |
| EBITDA | 1.20% | 4.41% | 3.23% | -3.80% | -14.66% |
| EPS Basic | 52.41% | 60.07% | 54.08% | 47.04% | 41.82% |
| Normalized Basic EPS | 54.75% | 46.95% | 39.83% | 31.46% | 23.75% |
| EPS Diluted | 52.41% | 60.07% | 54.08% | 47.04% | 41.82% |
| Normalized Diluted EPS | 54.75% | 46.95% | 39.83% | 31.46% | 23.75% |
| Average Basic Shares Outstanding | 125.95% | 101.45% | 83.31% | 61.71% | 39.31% |
| Average Diluted Shares Outstanding | 125.95% | 101.45% | 83.31% | 61.71% | 39.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |